P-glycoproteins and multidrug resistance

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 161-183

  Bellamy, William T ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; chemosensitization; MDR1; MRP; P glycoprotein

Indexed keywords

AMIODARONE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CEFOPERAZONE; CEPHARANTHINE; CHLOROQUINE; CHLORPROMAZINE; CYCLOSPORIN A; DILTIAZEM; DIPYRIDAMOLE; ERYTHROMYCIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; NICARDIPINE; POLYSORBATE 80; PROGESTERONE; PROPRANOLOL; QUINIDINE; QUININE; TACROLIMUS; TAMOXIFEN; TRIFLUOPERAZINE; VALSPODAR; VERAPAMIL;

CANCER; CANCER CHEMOTHERAPY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030001378     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.36.1.161     Document Type: Review

References (127)

1. Kessel D, Botterill V, Wodinsky I. 1968. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 28:938-41
2. Biedler JL, Riehm H. 1970. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30:1174-84
3. Bech-Hansen N, Till JE, Ling V. 1976. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J. Cell. Physiol. 88:23-31
4. Ling V, Thompson L. 1973. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83:103-16
5. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455: 152-62
6. Kartner N, Riordan JR, Ling V. 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-88
7. Ling V. 1982. Genetic basis of drug resistance in mammalian cells. In Drug and Hormone Resistance in Neoplasia, ed. N Bruchosky, J Goldie, 1:1-19. Boca Raton, FL: CRC Press
8. Beck WT, Danks MK. 1991. Characteristics of multidrug resistance in human tumor cells. See Ref. 127, pp.3-55
9. Bellamy WT, Dalton WS. 1994. Multidrug resistance in the laboratory and clinic. Adv. Clin. Chem. 31:1-61
10. Nielsen D, Skovsgaard T. 1992. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim. Biophys. Acta 1139:169-83
11. Gerlach JH, Kartner N, Bell DR, Ling V. 1986. Multidrug resistance. Cancer Surv. 5:25-46
12. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:137-71
13. Gros P, Ben NY, Croop JM, Housman DE. 1986. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-31
14. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. 1987. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77:142-44
15. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. 1989. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell. Biol. 9:3808-20
16. Roninson IB. 1991. Structure and evolution of P-glycoproteins. See Ref. 127, pp.189-211
17. Gros P, Raymond M, Housman D. 1991. Cloning and characterization of mouse mdr genes. See Ref. 127, pp.73-89
18. Juranka PF, Zastawny RL, Ling V. 1989. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3:2583-92
19. Ng WF, Sarangi F, Zastawny RL, Veinot DL, Ling V. 1989. Identification of members of the P-glycoprotein multigene family. Mol. Cell. Biol. 9:1224-32
20. Buschman E, Gros P. 1994. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein. Cancer Res. 54:4892-98
21. Melera P, Biedler J. 1991. Molecular and cytogenetic analysis of multidrug resistance-associated gene amplification in Chinese hamster, mouse sarcoma, and human neuroblastoma cells. See Ref. 127, pp.117-45
22. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. 1987. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J. 6:3325-31
23. Smit JJ, Schinkel AH, Oude ER, Groen AK, Wagenaar E, et al. 1993. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-62
24. Schinkel AH, Smit JM, Vantelli O, Beijnen JH, Wagenaar E, et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
25. Bradley G, Naik M, Ling V. 1989. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 49:2790-96
26. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, et al. 1986. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232:643-45
27. Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, et al. 1989. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388-95
28. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. 1987. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262:505-58
29. Ueda K, Pastan I, Gottesman MM. 1987. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 262:17432-36
30. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, et al. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49:729-39
31. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. 1990. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265:221-26
32. Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, et al. 1989. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 264:18031-40
33. Burt RK, Thorgeirsson SS. 1988. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J. Natl. Cancer Inst. 80:1383-86
34. Chaudhary PM, Roninson IB. 1993. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85:632-39
35. Chin KV, Chauhan SS, Pastan I, Gottesman MM. 1990. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1:361-65
36. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM. 1987. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236:1120-22
37. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, et al. 1993. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ. 4:147-57
38. Chin KV, Ueda K, Pastan I, Gottesman MM. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-62
39. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V 1993. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8:1529-35
40. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potesmil M, et al. 1993. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-59
41. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, et al. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-89
42. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, et al. 1986. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-89
43. Gros P, Croop J, Housman D. 1986. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-80
44. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. 1992. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89:8472-76
45. Yoshimura A, Kuwazuru Y, Sumizawa T, Ichikawa M, Ikeda S, et al. 1989. Cytoplasmic orientation and two-domain structure of the multidrug transporter, p-glycoprotein, demonstrated with sequence-specific antibodies. J. Biol. Chem. 264:16282-91
46. Zhang JT, Ling V. 1991. Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J. Biol. Chem. 266:18224-32
47. Zhang JT, Duthie M, Ling V. 1993. Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. J. Biol. Chem. 268:15101-10
48. Skach WR, Calayag MC, Lingappa VR. 1993. Evidence for an alternate model of human P-glycoprotein structure and biogenesis. J. Biol. Chem. 268:6903-8
49. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-42
50. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:18-21
51. Zamora JM, Pearce HL, Beck WT. 1988. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454-62
52. Bruggemarm EP, Currier SJ, Gottesman MM, Pastan I. 1992. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J. Biol. Chem. 267:21020-26
53. Zhang X, Collins KL, Greenberger LM. 1995. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J. Biol. Chem. 270:5441-48
54. Loo TW, Clarke DM. 1995. Membrane topology of a cysteine-less mutant of human p-glycoprotein. J. Biol. Chem. 270:843-48
55. Azzaria M, Schurr E, Gros P. 1989. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol. Cell. Biol. 9:5289-97
56. Currier SJ, Ueda K, Willingham MC, Pastan I, Gottesman MM. 1989. Deletion and insertion mutants of the multidrug transporter. J. Biol. Chem. 264: 14376-81
57. Higgins CF. 1992. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:67-113
58. Childs S, Yeh RL, Georges E, Ling V. 1995. Identification of a sister gene to P-glycoprotein. Cancer Res. 55:2029-34
59. Cordon-Cardo C, O'Brien JP. 1991. The multidrug resistance phenotype in human cancer. In Important Advances in Oncology, ed. VT DeVita, S Heliman, SA Rosenberg, pp.19-38. Philadelphia: Lippincott
60. Cordon CC, O'Brien JP, Casals D, Rittman GL, Biedler JL, et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-98
61. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1989. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37:159-64
62. Wilisch A, Noller A, Haadgretinger R, Weger S, Nussler V, et al. 1993. Mdr1/P-glycoprotein expression in natural killer (NK) cells enriched from peripheral or umbilical cord blood. Cancer Lett. 69:139-48
63. Chaudhary PM, Roninson IB. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94
64. Brightman MW. 1989. The anatomic basis of the blood-brain barrier. In Implications of the Blood-Brain Barrier and Its Manipulation, ed. EA Neuwalt, pp. 53-83. New York: Plenum
65. Hegmann EJ, Bauer HC, Kerbel RS. 1992. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52:6969-75
66. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, et al. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51: 1427-37
67. Chan HS, Thorner PS, Haddad G, Ling V. 1990. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8:689-704
68. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. 1989. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J. Natl. Cancer Inst. 81:696-701
69. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, et al. 1993. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490-95
70. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, et al. 1991. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 51:2720-26
71. Bonadonna G, Valagussa P, Santoro A. 1986. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Int. Med. 104:739-46
72. Devita V, Serpick A, Carbone P. 1970. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Int. Med. 73:881-89
73. McLachlin J, Eglitis M, Ueda K, Kantoff P, Pastan I, et al. 1990. Expression of a human complementary DNA for the multidrug resistance gene in murine hematoppietic precursor cells with use of retroviral gene transfer. J. Natl. Cancer Inst. 82:1260-63
74. Tsuruo T. 1989. Circumvention of drug resistance with calcium channel blockers and monoclonal antibodies. Cancer Treat. Res. 48:73-95
75. FitzGerald DJ, Willingham MC, Cardareili CO, Hamada H, Tsuruo T, et al. 1987. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 84:4288-92
76. Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, et al. 1995. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J. Natl. Cancer Inst. 87:94-104
77. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, et al. 1991. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J. Natl. Cancer Inst. 83:1386-91
78. Kobayashi H, Dorai T, Holland JF, Ohnuma T. 1994. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54:1271-75
79. Holm PS, Scanlon KJ, Dietel M. 1994. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer 70:239-43
80. Scanlon KJ, Ishida H, Kashani-Sabet M. 1994. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. Natl. Acad. Sci. USA 91:11123-27
81. Tsuruo T, Iida H, Tsukagoshi S, Saturai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-72
82. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1982. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42: 4730-33
83. Beck WT. 1991. Modulators of P-glycoprotein-associated multidrug resistance. In Molecular and Clinical Advances in Anticancer Drug Resistance, ed. RF Ozols, pp. 151-70. Boston: Kluwer
84. Ford JM, Hait WN. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-99
85. Horton J, Thimmaiah K, Houghton J, Horowitz M, Houghton P. 1989. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenographs. Biochem. Pharm. 38:1727-36
86. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. 1991. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. USA 88:547-51
87. Bellamy WT, Odeleye A, Finley P, Huizenga B, Dalton WS, et al. 1993. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am. J. Pathol. 142:691-98
88. Mickisch GH, Pai LH, Siegsmund M, Campain J, Gottesman MM, Pastan I. 1993. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J. Urol. 149: 174-78
89. Bellamy WT, Odeleye A, Finley P, Huizenga E, Weinstein RS, Grogan TM. 1993. An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice. Proc. Am. Assoc. Cancer Res. 34:319 (Abstr.)
90. Bellamy W, Peng Y, Odeleye A, Huizenga E, Xu M, et al. 1994. The addition of cyclosporin A results in markedly elevated tissue levels of doxorubicin in the SCID mouse. Proc. Am. Assoc. Cancer Res. 35:354 (Abstr.)
91. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, et al. 1989. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7:415-24
92. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9:17-24
93. Sonneveld P, Schoster M, de Leeuw K. 1994. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J. Clin. Oncol. 12:1584-91
94. Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, et al. 1992. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 10:1624-34
95. List AF, Spier C, Greer J, Wolff S, Hutter J, et al. 1993. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11:1652-60
96. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, et al. 1993. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 53:4837-42
97. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, et al. 1992. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10:1635-42
98. Yuen AR, Sikic BI. 1994. Multidrug resistance in lymphomas. J. Clin. Oncol. 12:2453-59
99. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, et al. 1987. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res. 47:5455-60
100. Danks MK, Yalowich JC, Beck WT. 1987. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1297-301
101. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. 1988. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-69
102. Fernandes DJ, Danks MK, Beck WT. 1990. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 29:4235-41
103. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-54
104. Krishnamachary N, Center MS. 1993. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:3658-61
105. Grant CE, Valdimarsson G, Hipfner D, Almquist KC, Cole SPC, Deeley RG. 1994. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:357-61
106. Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA. 1994. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 54:1649-52
107. Zaman G, Flens MJ, Van LM, De HM, Mülder HS, Lankelma J, et al. 1994. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91:8822-26
108. Cole S, Sparks KE, Fraser K, Loe DW, Grant CE, et al. 1994. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:5902-10
109. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, et al. 1994. Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 54:4557-63
110. Hipfner DR, Gauldie SD, Deeley RG, Cole S. 1994. Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54:5788-92
111. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole S, Deeley RG. 1995. Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res. 55:102-10
112. Ma L, Krishnamachary N, Center MS. 1995. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-43
113. Zhu Q, Center MS. 1994. Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Cancer Res. 54 4488-92
114. Leier I, Jedlitschky G, Buchholz U, Cole S, Deeley RG, Keppler D. 1994. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:27807-10
115. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. 1995. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 208:345-52
116. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. 1994. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 8:2163-68
117. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, et al. 1995. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186-93
118. Burger H, Nooter K, Sonneveld P, Van WK, Zaman G, Stoter G. 1994. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br. J. Haematol. 88:348-56
119. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, et al. 1993. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1475-79
120. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, et al. 1995. The drug resistance related protein LRP is a major vault protein. Proc. Am. Assoc. Cancer Res. 36:323 (Abstr.)
121. Kedersha NL, Rome LH. 1986. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J. Cell Biol. 103:699-709
122. Vasu SK, Kedersha NL, Rome LH. 1993. cDNA cloning and disruption of the major vault protein a gene (mvpA) in Dictyostelium discoideum. J. Biol. Chem. 268:15356-60
123. Chugani DC, Rome LH, Kedersha NL. 1993. Evidence that vault ribonucleoprotein particles localize to the nucleopore complex. J. Cell Sci. 106: 23-29
124. Kedersha NL, Heuser JE, Chugani DC, Rome LH. 1991. Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J. Cell Biol. 112:225-35
125. Slovak ML, Ho J, Deeley RG, Cole SPC, de Vries EGE, et al. 1995. The drug resistance related protein LRP maps proximal to MRP on the short arm of chromosome 16. Proc. Am. Assoc. Cancer Res. 36:19 (Abstr.)
126. Scheper RJ, Scheffer GL, Flens M, Izquierdo MA, van der Valk P, et al. 1994. Molecular and clinical characterization of the LRP protein associated with non-P-glycoprotein multidrug resistance. Proc. Am. Assoc. Cancer Res. 35:344 (Abstr.)
127. Roninson IB, ed. 1991. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum